Seeing Is Believing

Currently out of the existing stock ratings of Justin Zelin, 100 are a BUY (93.46%), 7 are a HOLD (6.54%).
Analyst Justin Zelin, currently employed at BTIG, carries an average stock price target met ratio of 16.04% that have a potential upside of 26.91% achieved within 62 days.
Justin Zelin’s has documented 196 price targets and ratings displayed on 32 stocks. The coverage is on Healthcare, Industrials, Energy sectors.
Most recent stock forecast was given on IBRX, Immunitybio at 23-Jan-2026.
Analyst best performing recommendations are on MRSN (MERSANA THERAPEUTICS).
The best stock recommendation documented was for MRSN (MERSANA THERAPEUTICS) at 8/13/2025. The price target of $17 was fulfilled within 92 days with a profit of $10.19 (149.63%) receiving and performance score of 16.26.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 16-Oct-2017
$20
$15.71 (366.20%)
$20
15 days ago
(19-Mar-2026)
0/15 (0%)
$15.46 (340.53%)
Buy Since 29-Apr-2025
$19
$14.71 (342.89%)
$20
4 months 22 days ago
(12-Nov-2025)
0/3 (0%)
$14.06 (284.62%)
Buy Since 02-Jun-2025
$20
$15.71 (366.20%)
$19
7 months 19 days ago
(15-Aug-2025)
0/2 (0%)
$12.87 (180.50%)
Buy Since 30-May-2024
$20
$15.55 (349.44%)
$21
10 months 18 days ago
(16-May-2025)
0/2 (0%)
$13.9 (227.87%)
Buy Since 19-Feb-2025
$15
$10.71 (249.65%)
$15
1 years 10 days ago
(24-Mar-2025)
0/2 (0%)
$9.88 (192.97%)
Which stock is Justin Zelin is most bullish on?
Which stock is Justin Zelin is most reserved on?
What Year was the first public recommendation made by Justin Zelin?